Skip to main content

Table 4 First-line immunochemotherapy for marginal zone lymphoma

From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Study Regimen Disease type Trial phase type No. of patients Overall RR (CR + PR) PFS OS
Salar et al. [19] R-fludarabine Any stage MALT lymphoma II 22 100% (62 + 38) 2-year, 88% 2-year, 100%
Zucca et al. [23, 25] R–Cb Any stage MALT lymphoma III (R–Cb vs R vs Cb) 132 (total 401) 94.7% (78.8 + 15.9) 5-year, 68%a 5-year, 90%
Kang et al. [24] R–CVP Stage III/IV MZL II 41 87.5% (60 + 27.5) 3-year, 59% 3-year, 94%
Salar et al. [26, 27] R–B Any stage MALT lymphoma II 57 100% 7-year, 92.8% 7-year, 94.7%
Oh (present study) R–CVP followed by R-maintenance Stage III/IV MZL II 45 3-year, 81% 3-year, 90%
  1. PFS progression-free survival, OS overall survival, CR complete response, PR partial response, MZL marginal zone B-cell lymphoma, MALT mucosa-associated lymphoid tissue, R–CVP rituximab-cyclophosphamide, vincristine, and prednisolone, R–Cb rituximab–chlorambucil, R–B rituximab–bendamustine
  2. aEvent-free survival